|
[1]
|
Johnson, D.B., et al. (2016) Fulminant Myocarditis with Combination Immune Checkpoint Blockade. The New England Journal of Medicine, 375, 1749-1755. [Google Scholar] [CrossRef]
|
|
[2]
|
Morgado, M., et al. (2020) Management of the Adverse Effects of Immune Checkpoint Inhibitors. Vaccines (Basel), 8, 575. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Ramos-Casals, M., et al. (2020) Immune-Related Adverse Events of Checkpoint Inhibitors. Nature Reviews Disease Primers, 6, 38. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Bagchi, S., Yuan, R. and Engleman, E.G. (2021) Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annual Review of Pathology: Mechanisms of Disease, 16, 223-249. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Wang, R., Lin, N., Mao, B.B. and Wu, Q. (2021) The Efficacy of Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Meta-Analysis Based on 40 Cohorts Incorporating 3697 Individuals. Journal of Cancer Research and Clinical Oncology. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Finn, R.S., et al. (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. The New England Journal of Medicine, 382, 1894-1905. [Google Scholar] [CrossRef]
|
|
[7]
|
Abu-Sbeih, H. and Wang, Y. (2020) Hepatobiliary Adverse Events. Advances in Experimental Medicine and Biology, 1244, 271-276. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Brahmer, J.R., et al. (2018) Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 36, 1714-1768. [Google Scholar] [CrossRef]
|
|
[9]
|
Wolchok, J.D., et al. (2017) Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The New England Journal of Medicine, 377, 1345-1356. [Google Scholar] [CrossRef]
|
|
[10]
|
Mok, T.S.K., et al. (2019) Pembrolizumab versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. The Lancet, 393, 1819-1830. [Google Scholar] [CrossRef]
|
|
[11]
|
Rini, B.I., et al. (2019) Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England Journal of Medicine, 380, 1116-1127. [Google Scholar] [CrossRef]
|
|
[12]
|
El-Khoueiry, A.B., et al. (2017) Nivolumab in Patients with Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial. The Lancet, 389, 2492-2502. [Google Scholar] [CrossRef]
|
|
[13]
|
Zhu, A.X., et al. (2018) Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib (KEYNOTE-224): A Non-Randomised, Open-Label Phase 2 Trial. The Lancet Oncology, 19, 940-952. [Google Scholar] [CrossRef]
|
|
[14]
|
Duffy, A.G., et al. (2017) Tremelimumab in Combination with Ablation in Patients with Advanced Hepatocellular Carcinoma. Journal of Hepatology, 66, 545-551. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Kitagataya, T., et al. (2020) Prevalence, Clinical Course, and Predictive Factors of Immune Checkpoint Inhibitor Monotherapy-Associated Hepatitis in Japan. Journal of Gastroenterology and Hepatology, 35, 1782-1788. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
De Martin, E., Michot, J.-M., Rosmorduc, O., Guettier, C. and Samuel, D. (2020) Liver Toxicity as a Limiting Factor to the Increasing Use of Immune Checkpoint Inhibitors. JHEP Reports, 2, Article ID: 100170. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Daniello, L., et al. (2021) Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer. Frontiers in Oncology, 11, Article ID: 703893. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Zhong, L., Wu, Q., Chen, F.C., Liu, J.J. and Xie, X.H. (2021) Immune-Related Adverse Events: Promising Predictors for Efficacy of Immune Checkpoint Inhibitors. Cancer Immunology, Immunotherapy, 70, 2559-2576. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Yokohama, K., et al. (2020) Liver Dysfunction Is Associated with Poor Prognosis in Patients after Immune Checkpoint Inhibitor Therapy. Scientific Reports, 10, Article No. 14470. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Affolter, T., et al. (2019) Inhibition of Immune Checkpoints PD-1, CTLA-4, and IDO1 Coordinately Induces Immune-Mediated Liver Injury in Mice. PLoS ONE, 14, e0217276. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Fessas, P., et al. (2019) Immunotoxicity from Checkpoint Inhibitor Therapy: Clinical Features and Underlying Mechanisms. Immunology, 159, 167-177. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Mizuno, K., et al. (2020) Real World Data of Liver Injury Induced by Immune Checkpoint Inhibitors in Japanese Patients with Advanced Malignancies. Journal of Gastroenterology, 55, 653-661. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Zen, Y., et al. (2020) Immune-Related Adverse Reactions in the Hepatobiliary System: Second-Generation Check-Point Inhibitors Highlight Diverse Histological Changes. Histopathology, 76, 470-480. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Pi, B., et al. (2021) Immune-Related Cholangitis Induced by Immune Checkpoint Inhibitors: A Systematic Review of Clinical Features and Management. European Journal of Gastroenterology & Hepatology. [Google Scholar] [CrossRef]
|
|
[25]
|
Kawakami, H., et al. (2017) Imaging and Clinicopathological Features of Nivolumab-Related Cholangitis in Patients with Non-Small Cell Lung Cancer. Investigational New Drugs, 35, 529-536. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Onoyama, T., et al. (2020) Programmed Cell Death-1 Inhibitor-Related Sclerosing Cholangitis: A Systematic Review. World Journal of Gastroenterology, 26, 353-365. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Takinami, M., et al. (2021) Comparison of Clinical Features between Immune-Related Sclerosing Cholangitis and Hepatitis. Investigational New Drugs. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Denaro, N., et al. (2021) Unusual Fatal Outcome Following Administration of a Combination of Anti-PD1 and Anti-CTLA4 in Metastatic Renal Cell Carcinoma: Liver Toxicity Case Report and a Literature Review. European Journal of Case Reports in Internal Medicine, 8, Article ID: 002639. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Suzman, D.L., Pelosof, L., Rosenberg, A. and Avigan, M.I. (2018) Hepatotoxicity of Immune Checkpoint Inhibitors: An Evolving Picture of Risk Associated with a Vital Class of Immunotherapy Agents. Liver International, 38, 976-987. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Couey, M.A., et al. (2019) Delayed Immune-Related Events (DIRE) after Discontinuation of Immunotherapy: Diagnostic Hazard of Autoimmunity at a Distance. Journal for ImmunoTherapy of Cancer, 7, Article No. 165. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Tsung, I., et al. (2019) Liver Injury Is Most Commonly Due to Hepatic Metastases Rather than Drug Hepatotoxicity during Pembrolizumab Immunotherapy. Alimentary Pharmacology & Therapeutics, 50, 800-808. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Slawinski, G., et al. (2020) Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review. International Journal of Molecular Sciences, 21, 7195. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Vani, V., Regge, D., Cappello, G., Gabelloni, M. and Neri, E. (2020) Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy. Diagnostics (Basel), 10, 216. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Michot, J.M., et al. (2016) Immune-Related Adverse Events with Immune Checkpoint Blockade: A Comprehensive Review. European Journal of Cancer, 54, 139-148. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Xu, Y., Fu, Y., Zhu, B., Wang, J. and Zhang, B.C. (2020) Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities. Frontiers in Immunology, 11, 2023. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Shahabi, V., et al. (2013) Gene Expression Profiling of Whole Blood in Ipilimumab-Treated Patients for Identification of Potential Biomarkers of Immune-Related Gastrointestinal Adverse Events. Journal of Translational Medicine, 11, 75. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Valpione, S., et al. (2018) Sex and Interleukin-6 Are Prognostic Factors for Autoimmune Toxicity Following Treatment with Anti-CTLA4 Blockade. Journal of Translational Medicine, 16, 94. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Chaput, N., et al. (2019) Baseline Gut Microbiota Predicts Clinical Response and Colitis in Metastatic Melanoma Patients Treated with Ipilimumab. Annals of Oncology, 30, 2012. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Pollack, M.H., et al. (2018) Safety of Resuming Anti-PD-1 in Patients with Immune-Related Adverse Events (irAEs) during Combined Anti-CTLA-4 and Anti-PD1 in Metastatic Melanoma. Annals of Oncology, 29, 250-255. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Weber, J., et al. (2016) Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. Cancer Immunology Research, 4, 345-353. [Google Scholar] [CrossRef]
|
|
[41]
|
Simonaggio, A., et al. (2019) Evaluation of Readministration of Immune Checkpoint Inhibitors after Immune-Related Adverse Events in Patients with Cancer. JAMA Oncology, 5, 1310-1317. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Puzanov, I., et al. (2017) Managing Toxicities Associated with Immune Checkpoint Inhibitors: Consensus Recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. Journal for ImmunoTherapy of Cancer, 5, 95. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Gauci, M.L., et al. (2018) Immune-Related Hepatitis with Immunotherapy: Are Corticosteroids Always Needed? Journal of Hepatology, 69, 548-550. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
De Martin, E., et al. (2018) Characterization of Liver Injury Induced by Cancer Immunotherapy Using Immune Checkpoint Inhibitors. Journal of Hepatology, 68, 1181-1190. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Lombardi, A. and Mondelli, M.U. (2019) Review Article: Immune Checkpoint Inhibitors and the Liver, from Therapeutic Efficacy to Side Effects. Alimentary Pharmacology & Therapeutics, 50, 872-884. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Araujo, D.V., et al. (2021) Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events. Current Oncology, 28, 2173-2179. [Google Scholar] [CrossRef] [PubMed]
|